ACA
UTHR icon

Avoro Capital Advisors’s United Therapeutics UTHR Stock Holding History

Avoro Capital Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.51B Buy
2,777,777
+147,777
+6% +$83.2M 13.52% 1
2026
Q1 		$1.56B Buy
2,630,000
+23,940
+0.9% +$11.9M 15.34% 1
2025
Q4 		$1.27B Buy
2,606,060
+583,838
+29% +$272M 12.48% 1
2025
Q3 		$848M Sell
2,022,222
-347,778
-15% -$117M 10.96% 2
2025
Q2 		$681M Sell
2,370,000
-305,000
-11% -$91.2M 11.93% 2
2025
Q1 		$825M Sell
2,675,000
-85,300
-3% -$29.2M 12.87% 1
2024
Q4 		$974M Sell
2,760,300
-98,588
-3% -$36.2M 13.78% 1
2024
Q3 		$1.02B Hold
2,858,888
– – 14.94% 1
2024
Q2 		$911M Hold
2,858,888
– – 12.13% 1
2024
Q1 		$657M Hold
2,858,888
– – 7.66% 1
2023
Q4 		$629M Buy
2,858,888
+6,388
+0.2% +$1.47M 8.68% 2
2023
Q3 		$644M Sell
2,852,500
-57,499
-2% -$13.2M 10.05% 2
2023
Q2 		$642M Buy
2,909,999
+39,999
+1% +$8.86M 8.71% 3
2023
Q1 		$643M Buy
2,870,000
+5,000
+0.2% +$1.23M 9.53% 3
2022
Q4 		$797M Sell
2,865,000
-61,500
-2% -$15.5M 11.91% 1
2022
Q3 		$613M Sell
2,926,500
-43,500
-1% -$9.73M 11.32% 2
2022
Q2 		$700M Sell
2,970,000
-60,000
-2% -$12.2M 13.83% 1
2022
Q1 		$544M Sell
3,030,000
-5,000
-0.2% -$953K 9.92% 2
2021
Q4 		$656M Buy
3,035,000
+35,000
+1% +$6.87M 11.16% 3
2021
Q3 		$554M Hold
3,000,000
– – 8.7% 4
2021
Q2 		$538M Hold
3,000,000
– – 9.36% 3
2021
Q1 		$502M Buy
3,000,000
+150,000
+5% +$25M 8.67% 3
2020
Q4 		$433M Buy
+2,850,000
New +$374M 7.45% 3

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Avoro Capital Advisors's UTHR Position: Q2 2026 in Review

Avoro Capital Advisors increased its United Therapeutics (UTHR) stake by 5.6% in Q2 2026, buying an estimated $83.2M and bringing the position to 2,777,777 shares worth $1.51B. The position accounts for 13.52% of the portfolio, ranked #1.

Avoro Capital Advisors first reported a position in UTHR in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.56B in Q1 2026. 879 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Avoro Capital Advisors held 2,777,777 shares of United Therapeutics worth $1.51B as of Q2 2026.
  • Avoro Capital Advisors bought 147,777 United Therapeutics shares in Q2 2026, an estimated $83.2M.
  • United Therapeutics made up 13.52% of Avoro Capital Advisors's portfolio in Q2 2026, its #1 holding.
  • Avoro Capital Advisors first reported a position in United Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Avoro Capital Advisors's United Therapeutics position peaked at $1.56B in Q1 2026.
  • 879 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Avoro Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.